



Tasmania – Statewide antimicrobial benchmarking report for acute inpatient aggregate usage rates

January 2023 – June 2023

Antibacterial utilisation rates provided in this report are calculated using the number of defined daily doses (DDDs) of the antibacterial class consumed each month per 1,000 occupied bed days.

Contributing hospitals are assigned to Australian Institute for Health and Welfare (AIHW) defined peer groups.¹ Contributing hospitals can find their de-identifying code via the NAUSP Portal 'Maintain My Hospital' drop-down menu.


DDD values for each antimicrobial are assigned by the World Health Organization based on the “assumed average maintenance dose per day for the main indication in adults”. DDDs are reviewed annually by the WHO as dosing recommendations change over time. For more information refer to:

https://www.whocc.no/atc_ddd_methodology/purpose_of_the_atc_ddd_system/.

The chart below presents the acute aggregated antibacterial usage rates for the 4 respective contributing hospitals over the six-month period from 1 January 2023 to 30 June 2023. Unless otherwise specified, the aggregate rates include all acute care areas of the hospital, excluding usage in the emergency department and the operating theatre.

¹ AIHW. *Hospital resources 2017-18: Australian hospital statistics*. Available from <https://www.aihw.gov.au/reports/hospitals/hospital-resources-2017-18-ahs/data>

Chart 1: Total hospital antibacterial usage rates (DDD/1000 OBD) in NAUSP contributor hospitals, by peer group, Tasmania, January-June 2023 (excludes Emergency Department and Operating Theatre)



Alimentary antibiotics = rifaximin, fidaxomicin. *Other = amphenicols, antimycotics, combinations for eradication of *Helicobacter pylori*, monobactams, nitrofurans, linezolid, daptomycin, other cephalosporins, polymyxins, rifamycins, second-generation cephalosporins, steroids, streptogramins and streptomycin.

This report includes data from the following 4 hospitals in Tasmania:

Launceston General Hospital
Royal Hobart Hospital

North West Regional Hospital
Mersey Community Hospital

| ANTIBACTERIAL CLASSES | | | |
|--|-----------------------------|--|--|
| Alimentary antibiotics | fidaxomicin | Lincosamides | clindamycin |
| | paromomycin | | lincomycin |
| | rifaximin | | azithromycin |
| Aminoglycosides | amikacin | Macrolides | clarithromycin |
| | gentamycin | | erythromycin |
| | neomycin | | roxithromycin |
| | tobramycin | | spiramycin |
| β-lactamase inhibitor combinations | amoxicillin - clavulanate | | Monobactams |
| | piperacillin - tazobactam | Nitrofurantoin derivatives | nitrofurantoin |
| β-lactamase resistant penicillins | dicloxacillin | Polymyxins | colistin |
| | flucloxacillin | | polymyxin B |
| β-lactamase sensitive penicillins | benzathine benzylpenicillin | | cefaclor |
| | benzylpenicillin | | cefamandole |
| | phenoxymethylpenicillin | | cefotetan |
| | procaine benzylpenicillin | cefoxitin | |
| Carbapenems | doripenem | cefuroxime | |
| | ertapenem | Steroid antibacterials | fusidic acid |
| | imipenem - cilastatin | Streptogramins | pristinamycin |
| | meropenem | Streptomycins | streptomycin |
| | meropenem - vaborbactam | Sulfonamide-trimethoprim combinations | sulfamethoxazole - trimethoprim |
| Extended-spectrum penicillins | amoxicillin | Tetracyclines | doxycycline |
| | ampicillin | | minocycline |
| | pivmecillinam | | tetracycline |
| | temocillin | | tigecycline |
| First-generation cephalosporins | cefalexin | | Third-generation cephalosporins |
| | cefalotin | cefotaxime | |
| | cefazolin | ceftazidime | |
| Fluoroquinolones | ciprofloxacin | ceftazidime - avibactam | |
| | levofloxacin | ceftriaxone | |
| | moxifloxacin | Trimethoprim | trimethoprim |
| | norfloxacin | Other (including other cephalosporins and penems) | ceftaroline fosamil |
| Fourth-generation cephalosporins | cefepime | | ceftolozane - tazobactam |
| | cefpirome | | daptomycin |
| Glycopeptides | dalbavancin | | faropenem |
| | oritavancin | | fosfomicin |
| | teicoplanin | | linezolid |
| | vancomycin | | rifampicin |
| Imidazole derivatives | metronidazole | | tedizolid |
| Intermediate-acting sulfonamides | sulfadiazine | | |